Clinical consequences of consecutive self-expanding transcatheter heart valve iterations

H. G. Kroon · L. van Gils · F. Zivielo · M. P. H. van Wiechen · J. F. W. Ooms · Z. Rahhab · N. El Faqir · A.-M. Maugenest · J. A. Goudwaaard · P. Cummins · M. Lenzen · I. Kardys · J. Daemen · F. Mattace-Raso · P. P. T. de Jaegere · N. M. Van Mieghem

Accepted: 24 March 2021 / Published online: 29 April 2021 © The Author(s) 2021

Abstract
Objective To compare early clinical outcomes after transcatheter aortic valve implantation (TAVI) with three consecutive generations of self-expanding valves (SEVs).

Methods Clinical endpoints of consecutive patients who underwent TAVI with CoreValve, Evolut R or Evolut PRO were included in a prospective database.

Results TAVI was performed with CoreValve (n = 116), Evolut R (n = 160) or Evolut PRO (n = 92). Evolut R and Evolut PRO showed a tendency towards lower permanent pacemaker implantation (PPI) rates compared to CoreValve (CoreValve 27% vs Evolut R 16% vs Evolut PRO 18%, p = 0.091). By multivariable regression analysis CoreValve had a significantly higher risk for PPI (odds ratio (OR) 2.79, 95% confidence interval (CI) 1.31–5.94, p = 0.008) compared to Evolut R, while Evolut R and PRO were similar. Severe paravalvular leakage (PVL) occurred only with CoreValve, but no significant difference was observed in moderate PVL (10% vs 8% vs 6%, p = 0.49). CoreValve had a tendency towards a higher risk for more-than-mild PVL as compared with the Evolut platform (R + PRO) (OR 2.46, 95% CI 0.98–6.16, p = 0.055). No significant differences in all-cause mortality (7% vs 4% vs 1%, p = 0.10), stroke (6% vs 3% vs 2%, p = 0.21) or major vascular complications (10% vs 12% vs 4%, p = 0.14) were observed.

Conclusions TAVI with self-expanding valves was safe, and device iterations may result in a lower need for PPI. More-than-mild PVL seemed to occur less often with repositionable technology.

Keywords Transcatheter valve interventions · Aortic stenosis

Introduction
Transcatheter aortic valve implantation (TAVI) with the CoreValve transcatheter heart valve (THV) (Medtronic Inc., Minneapolis, MN, USA) demonstrated superior haemodynamic valve performance compared to surgery but resulted in more paravalvular leakage (PVL) and permanent pacemaker implantations (PPIs) [1]. The second-generation Evolut R has a smaller profile size and can be recaptured/repositioned to optimise device positioning and thereby limit both PVL and high-degree atrioventricular blocks [2]. Three large registries reported

What’s new?
- Transcatheter aortic valve implantation using Evolut R and Evolut PRO seemed to be associated with a lower need for permanent pacemaker implantations compared to CoreValve.
- More-than-mild paravalvular leakage seemed to occur less often with repositionable technology.
- Addition of a sealing wrap in Evolut PRO did not further reduce the risk for more-than-mild paravalvular leakage compared to Evolut R in this study.
a 14.7–19.3% PPI rate and a 1.9–7.7% rate of more-than-mild PVL [2–4]. The third-generation Evolut PRO features a pericardial wrap to further reduce PVL [5]. The US Evolut PRO Registry included 60 patients. More-than-mild PVL did not occur and 12% of patients required a PPI [5]. Both PPI and more-than-mild PVL are associated with worse clinical outcomes after TAVI [6, 7]. In this study we aimed to compare the early clinical performance of these three consecutive self-expanding valves (SEVs) in a real-world TAVI population.

Methods

Patient selection

All patients who underwent transfemoral or transsubclavian TAVI with one of the three SEVs for severe aortic stenosis (AS) between January 2012 and December 2018 were entered into our prospective database. Patients with a pacemaker at baseline were excluded (n = 37). All patients provided written informed consent for the TAVI procedure and subsequent data analysis. This present study was in accordance with the Declaration of Helsinki and approved by our center's Institutional Review Board.

Primary and secondary outcomes

The primary outcomes for this study were: (1) the need for PPI at 30 days, (2) more-than-mild PVL on pre-discharge transthoracic echocardiographic evaluation based on Valve Academic Research Consortium (VARC)-2 criteria [8]. Whether or not a patient required PPI was the treating physician’s decision but in general in compliance with the ESC guidelines on cardiac pacing and resynchronisation therapy. Secondary endpoints were in-hospital stroke, vascular and bleeding complications and 30-day all-cause mortality according to VARC-2 criteria [8]. All treated patients were discussed in our weekly plenary session with the interventionalists and came to our outpatient clinic at 30 days for adjudication of all events.

Data analysis

We defined the sheath to femoral artery ratio (SFAR) as the ratio between the sheath outer diameter (in millimetres) and the femoral artery minimal lumen diameter (in millimetres). The annular sizing ratio was defined as the ratio between the labelled prosthesis diameter and the perimeter-derived annular diameter. Continuous variables were presented as mean (±SD) or median (interquartile range, IQR) and categorical variables as n (%). The distribution of continuous variables was examined for normality through histograms and Q-Q plots. For the comparison of continuous variables between the three different THVs one-way ANOVA or the non-parametric Kruskal-Wallis test was performed, according to the distribution of the variables. For the comparison of categorical variables the Pearson χ² or Fisher exact test was used as appropriate. For ensuing pairwise comparisons, we applied Bonferroni corrections to account for multiple testing. Additionally, we performed multivariable logistic regression to estimate the effect of the three THVs on the need for PPI at 30 days. We entered THV type and added baseline covariates that displayed a difference with a p-value less than 0.10 and that are known (or theoretical) risk factors for the occurrence of PVL (annular anatomical features, calcification levels of left ventricular outflow tract (LVOT) or annulus). Lastly, we combined all Evolut R and PRO patients and compared this group to the CoreValve patients, as the newer generations were built on more or less the same fundamentals. All statistical analyses were performed with SPSS version 24.0 (IBM Corporation, Armonk, NY, USA). A two-sided value of p < 0.05 was considered statistically significant.

Results

A total of 368 (53% male) patients underwent TAVI with CoreValve (n = 116), Evolut R (n = 160) or Evolut PRO (n = 92). The overall median age and Society of Thoracic Surgeons (STS) predicted risk of mortality were 80 (IQR 74–84) years and 4.3% (IQR 2.8–6.3), respectively. TAVI was performed via the transfemoral route in 89% of cases. No significant differences were observed regarding moderate or severe LVOT and annular calcifications or the presence of (functional) bicuspid valves. All baseline characteristics are shown in Tab. 1.

Clinical outcomes among the three generations of SEV

TAVI with Evolut R and Evolut PRO was performed more often via a femoral approach (CoreValve 84% vs Evolut R 89% vs Evolut PRO 97%, p = 0.01), without pre-dilatation (79% vs 8% vs 12%, p < 0.005) and with post-dilatation (28% vs 42% vs 41%, p = 0.03). Repositioning was done twice as often with the Evolut R as with the Evolut PRO valve (35% vs 19%, p < 0.005). The SFAR was lower with the two newer generations, while the annular sizing ratio was higher. There was a lower PPI rate with Evolut R and Evolut PRO than
### Table 1  Baseline characteristics of patients and procedural details for the three self-expanding valves

|                          | CoreValve  | Evolut R  | Evolut PRO | **p-value** |
|--------------------------|------------|-----------|------------|-------------|
| **Baseline characteristics** |            |           |            |             |
| Male gender              | 68 (59%)   | 86 (54%)  | 42 (46%)   | 0.17        |
| Age (years)              | 80 (75–84) | 79 (73–84)| 80 (74–85) | 0.32        |
| STS score (%)            | 4.3 (3.1–5.7) | 4.2 (2.7–6.4) | 4.3 (2.5–6.5) | 0.86        |
| Creatinine at baseline (µmol/l) | 95 (75–128) | 98 (75–117) | 90 (74–117) | 0.56        |
| Body mass index (kg/m²)  | 27 ± 4     | 27 ± 5    | 27 ± 5    | 0.78        |
| Ischaemic heart disease  | 53 (46%)   | 70 (44%)  | 31 (34%)  | 0.18        |
| History of AVR/TAVI      | 5 (4%)     | 14 (9%)   | 7 (8%)    | 0.36        |
| Diabetes mellitus        | 38 (33%)   | 44 (28%)  | 29 (32%)  | 0.66        |
| Hypertension             | 87 (75%)   | 121 (76%) | 71 (77%)  | 0.93        |
| History of atrial fibrillation | 28 (24%) | 47 (29%)  | 22 (24%)  | 0.52        |
| History of stroke        | 21 (18%)   | 18 (11%)  | 14 (15%)  | 0.27        |
| Peripheral arterial disease | 43 (37%) | 80 (50%)  | 27 (29%)  | 0.003       |
| NYHA class ≥3            | 84 (75%)²  | 93 (58%)³ | 62 (68%)³ | 0.035       |
| Bicuspid valve (functional) | 9 (8%)     | 10 (6%)   | 7 (8%)    | 0.92        |
| Moderate or severe annulus calcification (Rosenhek) | 92 (79%) | 126 (79%) | 77 (84%) | 0.46        |
| Moderate or severe LVOT calcification | 20 (17%) | 22 (14%)  | 14 (15%) | 0.65        |
| **Procedural details**   |            |           |            |             |
| Femoral access           | 97 (84%)ᵇ | 142 (89%) | 89 (97%)ᵇ | 0.01        |
| Target access vessel diameter (mm) | 7.0 ± 1.6 | 6.7 ± 1.4ᶜ | 7.4 ± 1.3ᶜ | 0.002       |
| Sheath to femoral artery ratio | 1.03 (0.87–1.23ᵃᵇ) | 0.87 (0.75–0.97ᵃ) | 0.80 (0.72–0.93ᵇ) | <0.005 |
| Valve sizes (mm)         | 23 (2%)    | 7 (4%)    | 2 (2%)    |            |
| 26                       | 27 (23%)   | 49 (31%)  | 30 (33%)  |            |
| 29                       | 58 (50%)   | 78 (49%)  | 60 (65%)  |            |
| 31                       | 29 (25%)   | –         | –         |            |
| 34                       | –          | 26 (16%)  | –         |            |
| Perimeter derived annular diameter (mm) | 25.0 (23.4–26.7ᵃᵇ) | 23.9 (22.4–25.5ᵃ) | 23.8 (22.5–24.9ᵇ) | <0.005 |
| Annular sizing ratio     | 1.15 (1.10–1.20ᵃᵇ) | 1.19 (1.15–1.23ᵃ) | 1.18 (1.14–1.21ᵇ) | <0.005 |
| Depth of implantation (mm) | 7.0 ± 3.2  | 7.0 ± 3.3 | 7.2 ± 2.6 | 0.85        |
| Pre-dilatation           | 92 (79%)ᵃᵇ | 12 (8%)ᵃ | 11 (12%)ᵃ | <0.005     |
| Post-dilatation          | 32 (28%)ᵃᵇ | 67 (42%)ᵃ | 38 (41%)ᵃ | 0.03        |
| Repositioning used?      | –          | 56 (35%)  | 17 (19%)  | <0.005     |
| One time                 | 35 (4%)    | 6 (4%)    | 4 (4%)    | 0.47        |
| Two times                | 14 (7%)    | 2 (2%)    |            |            |
| Three times              | 4 (2%)     | 2 (2%)    |            |            |
| Four times               | 3 (2%)     | –         |            |            |
| Valve in valve during procedure | 8 (7%)   | 6 (4%)    | 4 (4%)    | 0.47        |
| Number of valves implanted | 1, range 1–3 | 1, range 1–3 | 1, range 1–2 | 0.23 |

Categorical variables are shown as n (%). Continuous variables are displayed as mean ± SD, median (interquartile range) or median, range. STS Society of Thoracic Surgeons, AVR aortic valve replacement, TAVI transcatheter aortic valve implantation, NYHA New York Heart Association, RBBB right bundle branch block, LBBB left bundle branch block, UNV unspecific intraventricular conduction defect, AV1B first-degree atrioventricular block, LAFB left anterior fascicular block, LPFB left posterior fascicular block

ᵃᵇᶜ p < 0.05 for pairwise comparisons with Bonferroni correction

Consecutive self-expanding valves
Advertisement placed here.

Houten 2021
Table 2  Clinical outcomes with Medtronic CoreValve, Evolut R and Evolut PRO

| Clinical outcomes                                      | CoreValve \((n=116)\) | Evolut R \((n=160)\) | Evolut PRO \((n=92)\) | \(p\)-value |
|--------------------------------------------------------|-------------------------|-----------------------|------------------------|-------------|
| Permanent pacemaker post-TAVI owing to:                |                         |                       |                        |             |
| AV3B                                                   | 31 (27%)                | 26 (16%)              | 17 (18%)               | 0.091       |
| AV2B (Mobitz II)                                       | 20 (65%)                | 23 (89%)              | 14 (82%)               | –           |
| AF with bradycardia                                    | 3 (10%)                 | 0 (0%)                | 0 (0%)                 | –           |
| Sick sinus syndrome                                    | 3 (10%)                 | 0 (0%)                | 0 (0%)                 | –           |
| Other                                                   | 2 (7%)                  | 2 (8%)                | 0 (0%)                 | –           |
| Mortality at 30 days                                    |                         |                       |                        | 0.10        |
| Moderate                                                | 15 (13%)                | 12 (8%)               | 5 (6%)                 | 0.11        |
| Severe                                                  | 11 (10%)                | 12 (8%)               | 5 (6%)                 |             |
| Minor vascular complication                             | 4 (3%)                  | 0 (0%)                | 0 (0%)                 |             |
| Major vascular complication                             | 11 (10%)                | 11 (7%)               | 3 (3%)                 | 0.21        |
| Minor bleeding                                          | 12 (10%)                | 19 (12%)              | 4 (4%)                 | 0.14        |
| Major or life-threatening bleeding                      | 7 (6%)                  | 15 (9%)               | 5 (5%)                 | 0.42        |
| Procedural AV3B                                         | 24 (21%)                | 29 (18%)              | 15 (17%)               | 0.74        |
| Procedural LBBB                                         | 65 (56%)                | 87 (55%)              | 51 (55%)               | 0.99        |
| Procedural RBBB                                         | 2 (2%)                  | 2 (1%)                | 0 (0%)                 | 0.48        |
| Temporary LBBB                                          | 37 (32%)                | 40 (25%)              | 30 (33%)               | 0.34        |
| Permanent LBBB                                          | 35 (30%)                | 51 (32%)              | 29 (32%)               | 0.95        |
| Temporary RBBB                                          | 4 (4%)                  | 10 (6%)               | 2 (2%)                 | 0.26        |
| Permanent RBBB                                          | 0 (0%)**                | 1 (1%)***              | 6 (7%)****              | 0.001       |
| AF                                                      | 16 (14%)***             | 8 (5%)*               | 3 (3%)**               | 0.005       |

Categorical variables are shown as \(n\) (%)

TAVI transcatheter aortic valve implantation, AV3B third-degree atrioventricular block, AV2B second-degree atrioventricular block, AF atrial fibrillation, LBBB left bundle branch block, RBBB right bundle branch block, AV1B first-degree atrioventricular block

*,**,*** \(p<0.05\) for pairwise comparisons with Bonferroni correction

with the CoreValve THV (27% vs 16% vs 18%, \(p=0.091\); see Tab. 2 and Electronic Supplementary Material: Fig. S1). Multivariable logistic regression analysis showed CoreValve TAVI to result in a higher need for PPI compared with Evolut R, but there was no difference between Evolut R and Evolut PRO (odds ratio (OR) 2.79, 95% confidence interval (CI) 1.31–5.94, \(p=0.008\) and OR 1.18, 95% CI 0.52–2.71, \(p=0.69\) respectively; Table 3). The univariate analyses of the pre-specified clinical endpoints can be found in the Electronic Supplementary Material (Tables S1 and S2). The incidence of PPI after CoreValve TAVI was higher than for the Evolut platform combined (R + PRO) (OR 2.56, 95% CI 1.29–5.08, \(p=0.007\)), as displayed in the Electronic Supplementary Material (Tables S3 and S4). Right bundle branch block (RBBB), first-degree atrioventricular block at baseline and deeper implantations were independent predictors for PPI.

Severe PVL was observed only with CoreValve (4% vs 0% vs 0%, \(p=0.014\), as displayed in Fig. 1. By multivariable regression CoreValve did not show a higher risk than Evolut R for moderate-to-severe PVL (OR 2.06, 95% CI 0.79–5.39, \(p=0.14\)). However, CoreValve showed a tendency towards a higher risk for moderate or severe PVL when compared to the combined Evolut platform (OR 2.46, 95% CI 0.98–6.16, \(p=0.055\)). Also, male gender and the need for post-dilatation were associated with a higher risk for more-than-mild PVL. Smaller annular sizing ratio (undersizing) and (functional) bicuspid valves were associated with significant PVL in univariate analysis, but not in multivariable analysis. No significant difference in all-cause mortality was observed among the three THVs (7% vs
The PPI rate was consistently higher with CoreValve, varying between 26% and 29% in high-risk patients [1, 11]. Multivariable regression analysis confirmed the higher PPI rate with CoreValve as compared with Evolut R and PRO. We reported previously that 50% of conduction disorders already started after pre-dilatation and before THV implantation [12]. One could speculate that less pre-dilatation in the Evolut R and PRO cohort could (partially) explain this lower PPI rate. Conversely, post-dilatation was performed more often with the two newer valves, and univariate analysis showed pre-dilatation and post-dilatation not to be significant predictors of PPI. Several design characteristics of the second-generation Evolut R valve may have been clinically relevant [13]. First, the ability to reposition/recapture the device could result in higher implantation depths (although not observed in the present study) [13]. Second, the radial force is distributed more consistently and homogeneously and may create less trauma to the His bundle [13]. Third, its inflow portion was redesigned to deliver a less traumatic implantation and oversizing as well as to achieve a higher implantation depth with a lower risk of embolisation. The Evolut PRO is similar, but comes with an outer porcine pericardial wrap at the risk of embolisation. The Evolut PRO is similar, but may create less trauma to the His bundle [13].

The incidence of more-than-mild PVL was higher with CoreValve (13%) than with the Evolut platform (8% and 6%). Our findings are in line with the 8–14% more-than-mild PVL in previous CoreValve reports and lower rates with Evolut R (1–8%) and Evolut PRO (0–6%) [1–5, 9–11]. More-than-mild PVL is associated with higher mortality rates at 1 year [7]. In our study CoreValve showed a tendency towards a higher risk for more-than-mild PVL compared to the Evolut platform, even when corrected for (relative) oversizing and bicuspid anatomy. Also, male gender and need for post-dilatation were associated with moderate-to-severe PVL. Male gender has been associated with more-than-mild PVL in previous CoreValve reports (8% and 6%). Our findings are in line with the 8–14% more-than-mild PVL in previous CoreValve reports and lower rates with Evolut R (1–8%) and Evolut PRO (0–6%) [1–5, 9–11]. More-than-mild PVL is associated with higher mortality rates at 1 year [7]. In our study CoreValve showed a tendency towards a higher risk for more-than-mild PVL compared to the Evolut platform, even when corrected for (relative) oversizing and bicuspid anatomy. Also, male gender and need for post-dilatation were associated with moderate-to-severe PVL. Male gender has been associated with more-than-mild PVL in the past, but the underlying mechanism is not completely understood [15]. Males have more extensive aortic root calcification than females, even with similar AS severity [16]. This may explain a higher rate of more-than-mild PVL and was

### Discussion

The main findings of this single-centre comparative study of three consecutive SEVs are:

1. The Evolut platform resulted in a lower PPI rate than CoreValve.
2. Severe PVL occurred only with CoreValve, not with the Evolut platform.
3. The sealing wrap feature of Evolut PRO did not further reduce PVL.

### Need for permanent pacemaker

The lower pacemaker rates of 16% and 18% following TAVI with the Evolut R and Evolut PRO THVs are in line with the currently reported rates, which vary between 15–20% and 12–19%, respectively [2–5, 9, 10].
also demonstrated in the SUKTAVI trial [15]. Extensive aortic root calcification may inhibit complete valve apposition, induce valve eccentricity with a higher risk for PVL and may require post-dilatation more often [17]. The Evolut PRO features a pericardial wrap to further reduce PVL at the expense of an additional 2-French in profile (14-F to 16-F) [9]. This 2-F larger profile may result in more complications at the access site because there is a direct correlation between SFAR and vascular complications [18]. However, we did not find more vascular complications or bleedings with Evolut PRO than with Evolut R. This may be explained by our growing experience with large-bore access site management. Alternatively, the fact that we reserved the Evolut R predominantly for patients with smaller, more calcified femoral arteries after the commercial launch of Evolut PRO may have hypothetically inflated bleeding and vascular complication rates with Evolut R and skewed the comparison. The overall 30-day all-cause mortality and stroke rates of 4.1% and 3.5% are comparable to rates currently reported with SEVs in higher-risk, elderly patients, varying between 1.7–3.3% and 1.7–4.9%, respectively [1, 4, 5]. There were no significant differences in all-cause mortality or the occurrence of any stroke between the three device generations in our study. However, the combined Evolut (R+PRO) platform experience showed a tendency towards a lower 30-day mortality rate as compared to CoreValve. Intrinsic device iterations but also growing experience, a shift to lower-risk patients and procedure modifications over time may have contributed to the overall safety.

Study limitations

This was a single-centre, retrospective study and may be subject to inherent bias. The non-randomised, observational nature precludes any definite conclusions. Overall, TAVI experience and changing procedural execution over time cannot be completely corrected through statistical methods. Still, we believe our study population represents a real-world TAVI population and thus enhances generalisability. A low event rate restricted the number of confounders to account for in some analyses. Notably, we observed no significant differences in covariates closely related to PPI or significant PVL. The decision in favour of PPI was at the discretion of the treating physician, but high-degree atrioventricular block was the predominant reason for PPI and is in accordance with ESC guidelines on cardiac pacing. Also, the local policy was to leave a temporary pacemaker in situ less than 24h to prevent infections. Consequently, if a patient was pacemaker dependent after 24h, a permanent pacemaker was inserted. This may have prevented conduction disorders from resolving before PPI, but this was standard of care for all SEVs.

Conclusion

TAVI with SEVs was safe and device iterations may result in a lower need for PPI. More-than-mild PVL seemed to occur less often with repositionable technology.

Conflict of interest

P. P. de Jaegere is a proctor for Boston Scientific. N. M. Van Mieghem has received research grants from Abbott, Daiichi Sankyo, Medtronic, Boston Scientific, Edwards Lifesciences, Abbott and PulseCath, and is also an advisor to Abbott, Boston Scientific, Medtronic and PulseCath. H. G. Kroon, L. van Gils, E. Zivielo, M. van Wiechen, J. Ooms, Z. Rahhab, N. El Faquir, A.-M. Maugenest, J. A. Goudzwaard, P. Cummins, M. Lenzen, I. Kardys, J. Daemen and F. Mattace-Raso declare that they have no competing interests.

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless
indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370:1790–8.
2. Popma JJ, Reardon MJ, Khabbaz K, et al. Early clinical outcomes after transcatheter aortic valve replacement using a novel self-expanding bioprosthesis in patients with severe aortic stenosis who are suboptimal for surgery: results of the Evolut R US study. JACC Cardiovasc Inter. 2017;10:268–75.
3. Kalra SS, Firoozi S, Yeh J, et al. Initial experience of a second-generation self-expanding transcatheter aortic valve: the UK & Ireland Evolut R implanters' registry. JACC Cardiovasc Inter. 2017;10:276–82.
4. Grube E, Van Mieghem NM, Bleiziffer S, et al. Clinical outcomes with a repositionable self-expanding transcatheter aortic valve prosthesis: the international FORWARD study. J Am Coll Cardiol. 2017;70:845–53.
5. Forrest JK, Mangi AA, Popma JJ, et al. Early outcomes with the EvolutPRO repositionable self-expanding transcatheter aortic valve with pericardial wrap. JACC Cardiovasc Inter. 2018;11:160–8.
6. Chamandi C, Barbanti M, Munoz-Garcia A, et al. Long-term outcomes in patients with new permanent pacemaker implantation following transcatheter aortic valve replacement. JACC Cardiovasc Inter. 2018;11:301–10.
7. Athappan G, Patwardhan E, Tuzcu EM, et al. Incidence, predictors, and outcomes of aortic regurgitation after transcatheter aortic valve replacement: meta-analysis and systematic review of literature. J Am Coll Cardiol. 2013;61:1585–95.
8. Kappetein AP, Head SJ, Genereux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol. 2012;60:1438–54.
9. Hellhammer K, Piayda K, Afzal S, et al. The latest evolution of the Medtronic CoreValve system in the era of transcatheter aortic valve replacement: matched comparison of the Evolut PRO and Evolut R. JACC Cardiovasc Inter. 2018;11:2314–22.
10. Pagnesi M, Kim WK, Conradi L, et al. Transcatheter aortic valve replacement with next-generation self-expanding devices: a multicenter, retrospective, propensity-matched comparison of Evolut PRO versus Acurate Neo transcatheter heart valves. JACC Cardiovasc Inter. 2019;12:433–43.
11. Popma JJ, Adams DH, Reardon MJ, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol. 2014;63:1972–81.
12. Nuis RJ, Van Mieghem NM, Schultz CJ, et al. Timing and potential mechanisms of new conduction abnormalities during the implantation of the Medtronic CoreValve system in patients with aortic stenosis. Eur Heart J. 2011;32:2067–74.
13. Piazza N, Martucci G, Lachapelle K, et al. First-in-human experience with the Medtronic CoreValve Evolut R. EuroIntervention. 2014;9:1260–3.
14. Nijenhuis VJ, Van Dijk VE, Chaldoupis SM, Bult JC, Ten Berg JM. Severe conduction defects requiring permanent pacemaker implantation in patients with a new-onset left bundle branch block after transcatheter aortic valve implantation. EuroIntervention. 2017;19:1015–21.
15. Van Mieghem NM, Reardon MJ, Yakubov SJ, et al. Clinical outcomes of TAVI or SAVR in men and women with aortic stenosis at intermediate operative risk: a post hoc analysis of the randomized SURTAVI trial. EuroIntervention. 2020;16:833–41.
16. Aggarwal SR, Clavel MA, Messika-Zeitoun D, et al. Sex differences in aortic valve calcification measured by multidetector computed tomography in aortic stenosis. Circ Cardiovasc Imaging. 2013;6:40–7.
17. Di Martino LFM, Soliman OII, van Gils L, et al. Relation between calcium burden, echocardiographic stent frame eccentricity and paravalvular leakage after corevalve transcatheter aortic valve implantation. Eur Heart J Cardiovasc Imaging. 2017;18:648–53.
18. Hayashi K, Lefevre T, Chevalier B, et al. Transfemoral aortic valve implantation new criteria to predict vascular complications. JACC Cardiovasc Inter. 2011;4:851–8.